(Q34384137)

1 August 2017

title

Controlling postprandial hyperglycemia (English)

1 reference

1 August 2017

1 reference

Ratner RE

1

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 September 2001

1 reference

American Journal of Cardiology

1 August 2017

published in

1 reference

1 August 2017

volume

88

1 reference

1 August 2017

issue

6A

1 reference

1 August 2017

page(s)

26H-31H

1 reference

Postprandial hyperglycaemia and alpha-glucosidase inhibitors.

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901834-3

Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901834-3

Impaired glucose tolerance as a disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901834-3

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901834-3

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901834-3

The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901834-3

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901834-3

Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901834-3

Maternal postprandial glucose levels and infant birth weight: the Diabetes in Early Pregnancy Study. The National Institute of Child Health and Human Development--Diabetes in Early Pregnancy Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901834-3

The pharmacological treatment of hyperglycemia in NIDDM. American Diabetes Association

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901834-3

Mechanisms of the glycaemic effects of sulfonylureas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901834-3

Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901834-3

Glimepiride. A review of its use in the management of type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901834-3

A placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901834-3

Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901834-3

Repaglinide versus glyburide: a one-year comparison trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901834-3

Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901834-3

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901834-3

Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901834-3

Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901834-3

Thiazolidinediones in the treatment of insulin resistance and type II diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901834-3

Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901834-3

From the Food and Drug Administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901834-3

alpha-Glucosidase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901834-3

A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901834-3

The impact of pharmacotherapy on weight management in type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901834-3

Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901834-3

Type 2 diabetes mellitus: the grand overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901834-3

Triple oral antidiabetic therapy in type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901834-3

Drug therapy of postprandial hyperglycaemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901834-3

Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901834-3

10.1016/S0002-9149(01)01834-3

7 January 2021

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ybthhib4hfdjbnf3ypugaj3i7m

mapped directly with Wikidata item

30 July 2022

based on heuristic

Fatcat ID

release_ybthhib4hfdjbnf3ypugaj3i7m

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ybthhib4hfdjbnf3ypugaj3i7m

mapped directly with Wikidata item

30 July 2022

based on heuristic

https://api.fatcat.wiki/v0/release/ybthhib4hfdjbnf3ypugaj3i7m

1 reference